Pulmonary hypertension in systemic sclerosis with usual interstitial pneumonia
- PMID: 37069417
- DOI: 10.1007/s11739-023-03267-y
Pulmonary hypertension in systemic sclerosis with usual interstitial pneumonia
Abstract
Retrospective study comparing pulmonary hypertension risk in systemic sclerosis (SSc) and non-SSc interstitial lung disease patients with usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP). Retrospective analysis of 144 interstitial lung disease patients, 53 SSc (32 UIP and 21 NSIP) and 91 non-SSc (47 UIP and 44 NSIP). Pulmonary hypertension was diagnosed as pulmonary systolic artery pressure (PAPs) > 25 mmHg. All SSc and non-SSc patients with pulmonary hypertension were classified WHO Group 3. Pulmonary hypertension was identified in 21/32 (65.6%), 9/21 (42.8%), 14/47 (29.7%), and 28/44 (45.4%) SSc-UIP, SSc-NSIP, control-UIP, and control-NSIP groups, respectively. PAPs mean of SSc-UIP group was higher than control-UIP group (32.6 ± 9.8 vs 28.5 ± 6.6, p-value = 0.02). PAPs mean of SSc-NSIP group was lower than control-NSIP group (27.0 ± 7.1 vs 33.9 ± 8.8, p = 0.002). Frequency of patients with PAP > 25 mmHg in SSc-UIP group was 60% higher in comparison to control-UIP (OR = 1.62, 95% CI 0.51-5.16) and SSc-NSIP (OR = 1.60, 95% CI 0.45-5.70) groups. Logistic regression analysis estimating the linear trend per ten-unit increase in PAPs levels demonstrated an increment for the SSc-UIP group compared to the control-UIP (OR = 2.64, 95% CI 1.25-5.58, p = 0.01) and the control-NSIP (OR = 6.34, 95% CI 2.82-14.3, p < 0.001) groups. The case-control study confirms that pulmonary hypertension is frequently found in SSc patients and demonstrates, for the first time, a significant increased risk of pulmonary hypertension among SSc-UIP patients.
Keywords: Idiopathic pulmonary fibrosis; Interstitial lung disease; Non-specific interstitial pneumonia; Pulmonary hypertension; Systemic sclerosis; Usual interstitial pneumonia.
© 2023. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).
References
-
- Ciaffi J, Morabito MF, Ruscitti P et al (2021) Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data. Rheumatol International 41:129–137. https://doi.org/10.1007/s00296-020-04720-3 - DOI
-
- Royle JG, Lanyon PC, Grainge MJ, Abhishek A, Pearce FA (2018) The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. Clin Rheumatol 37:2103–2111. https://doi.org/10.1007/s10067-018-4182-3 - DOI - PubMed - PMC
-
- Cottin V, Brown KK (2019) Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory Res 20:13. https://doi.org/10.1186/s12931-019-0980-7 - DOI
-
- DeMizio DJ, Bernstein EJ (2019) Detection and classification of systemic sclerosis-related interstitial lung disease: a review. Curr Opin Rheumatol 31:553–560. https://doi.org/10.1097/BOR.0000000000000660 - DOI - PubMed - PMC
-
- Puppo F, Negrini S, Carbone RG (2021) Pulmonary vascular injury in systemic sclerosis: diagnosis and treatment. In: Carbone RG, Puppo F, Tapson VF (eds) Pulmonary vascular disorders, 3rd edn. Nova Science Publishers, New York, pp 469–484
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials